Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
<Group xmlns="http://hl7.org/fhir">
<id value="179786"/>
<meta>
<versionId value="3"/>
<lastUpdated value="2023-12-04T20:30:40.963Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Group</b><a name="179786"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Group "179786" Version "3" Updated "2023-12-04 20:30:40+0000" </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-exposure-definition.html">ExposureDefinition</a></p></div><p><b>Artifact related artifact</b>: </p><p><b>Artifact Title</b>: ExposureDefinition: Therapeutic-dose anticoagulation with heparin</p><p><b>Artifact URL</b>: <a href="https://fevir.net/resources/Group/179786">https://fevir.net/resources/Group/179786</a></p><p><b>Artifact Publisher</b>: Computable Publishing LLC</p><p><b>Artifact Copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>Artifact Contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>CombinationMethod</b>: any-of</p><blockquote><p><b>modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]</b></p></blockquote><p><b>identifier</b>: FEvIR Object Identifier: 179786</p><p><b>type</b>: animal</p><p><b>membership</b>: definitional</p><p><b>name</b>: ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin</p><p><b>description</b>: Description: therapeutic-dose anticoagulation with heparin
Note: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours.</p><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: ATTACC investigational arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen>24 hours, provided oxygen was required), whichever comes first.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: ACTIV-4a investigational arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: REMAP-CAP investigational arm</p><blockquote><p><b>CharacteristicTiming</b></p><blockquote><p><b>url</b></p><code>contextCode</code></blockquote><p><b>value</b>: Start of trial <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><blockquote><p><b>url</b></p><code>offset</code></blockquote><p><b>value</b>: 0-14</p><blockquote><p><b>url</b></p><code>text</code></blockquote><p><b>value</b>: Up to 14 days or until hospital discharge, whichever comes first.</p></blockquote><p><b>code</b>: Defined by CodeableConcept <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>exclude</b>: false</p></blockquote></div>
</text>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
<valueRelatedArtifact>
<type value="cite-as"/>
<citation
value="ExposureDefinition: Therapeutic-dose anticoagulation with heparin [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179786. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179786. Computable resource at: https://fevir.net/resources/Group/179786."/>
</valueRelatedArtifact>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-title">
<valueString
value="ExposureDefinition: Therapeutic-dose anticoagulation with heparin"/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-url">
<valueUri value="https://fevir.net/resources/Group/179786"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-publisher">
<valueString value="Computable Publishing LLC"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-copyright">
<valueMarkdown
value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-contact">
<valueContactDetail>
<telecom>
<system value="email"/>
<value value="support@computablepublishing.com"/>
</telecom>
</valueContactDetail>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Brian S. Alper"/>
</valueContactDetail>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method">
<valueCode value="any-of"/>
</extension>
<modifierExtension
url="http://hl7.org/fhir/StructureDefinition/artifact-status">
<valueCode value="active"/>
</modifierExtension>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="179786"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<type value="animal"/>
<membership value="definitional"/>
<name
value="ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin"/>
<description
value="Description: therapeutic-dose anticoagulation with heparin
Note: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours."/>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown value="ATTACC investigational arm"/>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
<extension url="contextCode">
<valueCodeableConcept>
<text value="Start of trial"/>
</valueCodeableConcept>
</extension>
<extension url="offset">
<valueRange>
<low>
<value value="0"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
<system value="http://unitsofmeasure.org"/>
<code value="d"/>
</high>
</valueRange>
</extension>
<extension url="text">
<valueString
value="Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen>24 hours, provided oxygen was required), whichever comes first."/>
</extension>
</extension>
<code>
<text value="Defined by CodeableConcept"/>
</code>
<valueCodeableConcept>
<text
value="Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."/>
</valueCodeableConcept>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown value="ACTIV-4a investigational arm"/>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
<extension url="contextCode">
<valueCodeableConcept>
<text value="Start of trial"/>
</valueCodeableConcept>
</extension>
<extension url="offset">
<valueRange>
<low>
<value value="0"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
<system value="http://unitsofmeasure.org"/>
<code value="d"/>
</high>
</valueRange>
</extension>
<extension url="text">
<valueString
value="Up to 14 days or until hospital discharge, whichever comes first."/>
</extension>
</extension>
<code>
<text value="Defined by CodeableConcept"/>
</code>
<valueCodeableConcept>
<text
value="Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal."/>
</valueCodeableConcept>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown value="REMAP-CAP investigational arm"/>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-timing">
<extension url="contextCode">
<valueCodeableConcept>
<text value="Start of trial"/>
</valueCodeableConcept>
</extension>
<extension url="offset">
<valueRange>
<low>
<value value="0"/>
</low>
<high>
<value value="14"/>
<unit value="days"/>
<system value="http://unitsofmeasure.org"/>
<code value="d"/>
</high>
</valueRange>
</extension>
<extension url="text">
<valueString
value="Up to 14 days or until hospital discharge, whichever comes first."/>
</extension>
</extension>
<code>
<text value="Defined by CodeableConcept"/>
</code>
<valueCodeableConcept>
<text
value="Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."/>
</valueCodeableConcept>
<exclude value="false"/>
</characteristic>
</Group>
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2023-12-17
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change